Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life‐changing drug or does lifestyle change the drug?
D. Vekic,J. Frew
DOI: https://doi.org/10.1111/ajd.12767
2018-08-01
Australasian Journal of Dermatology
Abstract:Hidradenitis suppurativa is a chronic inflammatory disease of intertriginous tissues manifesting as recurrent, painful nodules, abscesses, sinuses and scars with a profound physical and psychological impact. With an estimated prevalence of 0.03–4%, hidradenitis suppurativa is closely associated with the metabolic syndrome, androgen dysfunction and smoking. The clinical course and disease severity is variable, but a suboptimal response to traditional medical therapy is near universal. From 1 July 2017 the Australian Pharmaceutical Benefits Scheme has listed adalimumab (a fully human, monoclonal antibody inhibiting circulating tumour necrosis factor alpha) for moderate to severe hidradenitis suppurativa. This provides individuals living with hidradenitis suppurativa increased access to this affordable, potentially lifechanging therapy. The current Pharmaceutical Benefits Scheme criteria for adalimumab in hidradenitis suppurativa are listed in Table 1. Symptoms in a proportion of patients with hidradenitis suppurativa ameliorate when lifestyle factors such as ceasing smoking and weight loss therapy are addressed. However a significant minority have persistent severe and recalcitrant disease despite maximum lifestyle interventions, or are unsuccessful in addressing these factors. As these lifestyle issues are thought to contribute to inflammation in hidradenitis suppurativa, addressing them may have bearing on the efficacy of adalimumab. In other inflammatory diseases, no significant variations in the efficacy of adalimumab have been reported with regard to smoking status, bodyweight or diabetic status in Crohn disease, palmoplantar psoriasis or chronic plaque psoriasis. No similar studies have been undertaken in patients with hidradenitis suppurativa to date. Evidence exists in patients with psoriasis that smoking and diabetes predispose to an increased risk of serious infection (defined as a risk of death, permanent disability or prolonged hospitalisation) during treatment with adalimumab. Given the comparable association of both hidradenitis suppurativa and psoriasis with metabolic syndrome (hidradenitis suppurativa: OR 2.22; 95% CI 1.62– 3.06) and psoriasis (OR 2.14; 95% CI 1.84–2.48) it is prudent to assume that patients with hidradenitis suppurativa face a risk of infection. Indeed, hidradenitis suppurativa may have a stronger association with metabolic syndrome than psoriasis, particularly in light of the contribution of metabolic syndrome towards the inflammatory burden of the disease. This is exemplified by the reports of clinical improvement in patients with hidradenitis suppurativa with metformin and weight loss strategies including bariatric surgical intervention. Therefore, continuing to address lifestyle contributions to the activity of hidradenitis suppurativa, such as smoking, metabolic syndrome and weight loss (both before and during treatment with adalimumab) may have dual benefits. Firstly, it may help to minimise the risk of serious infection, and secondly, it may contribute to the ongoing control of inflammatory disease activity. Although current treatment guidelines and algorithms state that weight loss and smoking cessation should be discussed (if relevant) at every consultation, the data to support these recommendations is based upon data from other inflammatory disorders such as psoriasis and Crohn disease and may not be an accurate representation of the risk in hidradenitis suppurativa. The recent approval of adalimumab on the Pharmaceutical Benefits Scheme should be viewed as a triumph for patients with hidradenitis suppurativa. However, it is important for clinicians to recognise that until further evidence to the contrary emerges, the ongoing management of lifestyle contributions to hidradenitis suppurativa activity is still needed, even in the setting of effective adalimumab therapy.